August 20, 2024 - HYDERABAD, India--(BUSINESS WIRE)--Dr. Reddy’s Laboratories Ltd. (BSE: 500124, NSE: DRREDDY, NYSE: RDY, NSEIFSC: DRREDDY; along with its subsidiaries together referred to as “Dr. Reddy’s”), and its CRDMO arm Aurigene Pharmaceutical Services Limited (Aurigene), today announced that they have signed a non-binding Memorandum of Understanding (MoU) with Kainomyx, Inc., a US-based company with a proprietary platform that helps target cytoskeletal proteins of parasites, a novel mechanism of action, for the development and commercialization of affordable anti-malarial drug in the U.S., Europe, and in low and middle-income countries. The MoU remains subject to signing of a definitive agreement.

https://www.businesswire.com/news/home/20240820774139/en/Dr.-Reddy%E2%80%99s-Laboratories-Aurigene-Pharmaceutical-Services-and-Kainomyx-Announce-Potential-Partnership-for-Joint-Development-of-Affordable-Anti-Malarial-Drug